Literature DB >> 28282273

Fanning the Flames of Cancer Chemoresistance: Inflammation and Anticancer Therapy.

Kenneth P Olive1.   

Abstract

Entities:  

Mesh:

Year:  2017        PMID: 28282273      PMCID: PMC5456258          DOI: 10.1200/JOP.2017.021154

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN: 1554-7477            Impact factor:   3.840


× No keyword cloud information.
  10 in total

Review 1.  Vitamin D receptor agonists' anti-inflammatory properties.

Authors:  Jelena Vojinovic
Journal:  Ann N Y Acad Sci       Date:  2014-04-22       Impact factor: 5.691

Review 2.  Molecular mechanisms of cancer development in obesity.

Authors:  Melin J Khandekar; Paul Cohen; Bruce M Spiegelman
Journal:  Nat Rev Cancer       Date:  2011-11-24       Impact factor: 60.716

Review 3.  Functio Laesa: Cancer Inflammation and Therapeutic Resistance.

Authors:  Mingen Liu; Anusha Kalbasi; Gregory L Beatty
Journal:  J Oncol Pract       Date:  2017-03       Impact factor: 3.840

Review 4.  Systemic inflammation, cachexia and prognosis in patients with cancer.

Authors:  Christopher Deans; Stephen J Wigmore
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2005-05       Impact factor: 4.294

5.  Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism.

Authors:  Haoqiang Ying; Alec C Kimmelman; Costas A Lyssiotis; Sujun Hua; Gerald C Chu; Eliot Fletcher-Sananikone; Jason W Locasale; Jaekyoung Son; Hailei Zhang; Jonathan L Coloff; Haiyan Yan; Wei Wang; Shujuan Chen; Andrea Viale; Hongwu Zheng; Ji-hye Paik; Carol Lim; Alexander R Guimaraes; Eric S Martin; Jeffery Chang; Aram F Hezel; Samuel R Perry; Jian Hu; Boyi Gan; Yonghong Xiao; John M Asara; Ralph Weissleder; Y Alan Wang; Lynda Chin; Lewis C Cantley; Ronald A DePinho
Journal:  Cell       Date:  2012-04-27       Impact factor: 41.582

6.  Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer.

Authors:  Sunil R Hingorani; William P Harris; J Thaddeus Beck; Boris A Berdov; Stephanie A Wagner; Eduard M Pshevlotsky; Sergei A Tjulandin; Oleg A Gladkov; Randall F Holcombe; Ronald Korn; Natarajan Raghunand; Samuel Dychter; Ping Jiang; H Michael Shepard; Craig E Devoe
Journal:  Clin Cancer Res       Date:  2016-01-26       Impact factor: 12.531

7.  Risk of pancreatic adenocarcinoma in patients with hereditary pancreatitis: a national exhaustive series.

Authors:  Vinciane Rebours; Marie-Christine Boutron-Ruault; Matthieu Schnee; Claude Férec; Frédérique Maire; Pascal Hammel; Philippe Ruszniewski; Philippe Lévy
Journal:  Am J Gastroenterol       Date:  2008-01       Impact factor: 10.864

Review 8.  Mounting Pressure in the Microenvironment: Fluids, Solids, and Cells in Pancreatic Ductal Adenocarcinoma.

Authors:  Christopher C DuFort; Kathleen E DelGiorno; Sunil R Hingorani
Journal:  Gastroenterology       Date:  2016-04-09       Impact factor: 22.682

Review 9.  Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms.

Authors:  Eran Elinav; Roni Nowarski; Christoph A Thaiss; Bo Hu; Chengcheng Jin; Richard A Flavell
Journal:  Nat Rev Cancer       Date:  2013-11       Impact factor: 69.800

10.  Neural innervation stimulates splenic TFF2 to arrest myeloid cell expansion and cancer.

Authors:  Zina Dubeykovskaya; Yiling Si; Xiaowei Chen; Daniel L Worthley; Bernhard W Renz; Aleksandra M Urbanska; Yoku Hayakawa; Ting Xu; C Benedikt Westphalen; Alexander Dubeykovskiy; Duan Chen; Richard A Friedman; Samuel Asfaha; Karan Nagar; Yagnesh Tailor; Sureshkumar Muthupalani; James G Fox; Jan Kitajewski; Timothy C Wang
Journal:  Nat Commun       Date:  2016-02-04       Impact factor: 14.919

  10 in total
  4 in total

Review 1.  Cellular determinants and therapeutic implications of inflammation in pancreatic cancer.

Authors:  Meredith L Stone; Gregory L Beatty
Journal:  Pharmacol Ther       Date:  2019-05-31       Impact factor: 12.310

Review 2.  The interplay between innate and adaptive immunity in cancer shapes the productivity of cancer immunosurveillance.

Authors:  Renee B Chang; Gregory L Beatty
Journal:  J Leukoc Biol       Date:  2020-04-09       Impact factor: 4.962

3.  Pre-treatment inflammatory biomarkers predict early treatment response and favorable survival in patients with metastatic colorectal cancer who underwent first line cetuximab plus chemotherapy.

Authors:  Jinling Jiang; Tao Ma; Wenqi Xi; Chen Yang; Junwei Wu; Chenfei Zhou; Nan Wang; Zhenggang Zhu; Jun Zhang
Journal:  Cancer Manag Res       Date:  2019-09-24       Impact factor: 3.989

4.  The platelet to lymphocyte ratio is a potential inflammatory marker predicting the effects of adjuvant chemotherapy in patients with stage II colorectal cancer.

Authors:  Yu Fu; Xiaowan Chen; Yongxi Song; Xuanzhang Huang; Quan Chen; Xinger Lv; Peng Gao; Zhenning Wang
Journal:  BMC Cancer       Date:  2021-07-08       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.